Sex differences in the effectiveness of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in patients with congestive heart failure - A population study

European Journal of Heart Failure

Volumn 9, Issue 6-7, 2007, Pages 602-609

  Hudson, Marie ^a   Rahme, Elham ^a   Behlouli, Hassan ^a   Sheppard, Richard ^b   Pilote, Louise ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Angiotensin converting enzyme inhibitors; Angiotensin receptor blockers; Congestive heart failure; Sex differences

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; CAPTOPRIL; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPROSARTAN; FOSINOPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; PERINDOPRIL; QUINAPRIL; RAMIPRIL; TELMISARTAN; VALSARTAN;

ADULT; AGED; ARTICLE; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; DRUG USE; HOSPITAL CARE; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; SEX DIFFERENCE; SURVIVAL; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COHORT STUDIES; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; QUEBEC; RETROSPECTIVE STUDIES; SEX CHARACTERISTICS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 34247898971     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2007.02.001     Document Type: Article

References (31)

1. American Heart Association. Heart disease and stroke statistics - 2005 update (2005), American Heart Association, Dallas, Texas
2. Lloyd-Jones D.M., Larson M.G., Leip E.P., et al. Framingham Heart Study. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 106 24 (2002) 3068-3072
3. Tipnis S.R., Hooper N.M., Hyde R., Karran E., Christie G., and Turner A.J. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 275 43 (2000) 33238-33243
4. Donoghue M., Hsieh F., Baronas E., et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 87 5 (2000) E1-E9
5. Flather M.D., Yusuf S., Kober L., et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 355 9215 (2000) 1575-1581
6. Lee V.C., Rhew D.C., Dylan M., Badamgarav E., Braunstein G.D., and Weingarten S.R. Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med 141 9 (2004) 693-704
7. Pitt B., Poole-Wilson P.A., Segal R., et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 355 9215 (2000) 1582-1587
8. Jong P., Gong Y., Liu P.P., Austin P.C., Lee D.C., and Tu J.V. Care and outcomes of patients newly hospitalized for heart failure in the community treated by cardiologists compared to other specialists. Circulation 108 (2003) 184-191
9. Goff D.C., Pandey D.K., Chan F.A., Ortiz C., and Nichaman M.Z. Congestive heart failure in the United States - is there more than meets the I(CD Code)? The Corpus Christi Heart Project. Arch Int Med 160 (2000) 197-202
10. Hudson M., Richard H., and Pilote L. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study. BMJ 330 7504 (2005) 1370
11. Levy A.R., Tamblyn R.M., Fitchett D., McLeod P.J., and Hanley J.A. Coding accuracy of hospital discharge data for elderly survivors of myocardial infarction. Can J Cardiol 15 (1999) 1277-1282
12. Lee D.S., Austin P.C., Rouleau J.L., Liu P.P., Naimark D., and Tu J.V. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 290 19 (2003) 2581-2587
13. Granger C.B., McMurray J.J., Yusuf S., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362 9386 (2003) 772-776
14. Pfeffer M.A., McMurray J.J., Velazquez E.J., et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 20 (2003) 1893-1906
15. McMurray J.J., Ostergren J., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362 9386 (2003) 767-771
16. Cohn J.N., Tognoni G., and Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 23 (2001) 1667-1675
17. Pitt B., Segal R., Martinez F.A., et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349 (1997) 747-752
18. McKelvie R.S., Yusuf S., Pericak D., et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 100 (1999) 1056-1064
19. Dickstein K., Kjekshus J., and OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal trial in myocardial infarction with angiotensin II antagonist losartan. Lancet 360 9335 (2002) 752-760
20. Turnbull F., and Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events: results of prospectively designed overviews of randomised trials. Lancet 362 9395 (2003) 1527-1535
21. Redfield M.M., Jacobsen S.J., Burnett Jr. J.C., Mahoney D.W., Bailey K.R., and Rodeheffer R.J. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 289 2 (2003) 194-202
22. Bleumink G.S., Schut A.F., Sturkenboom M.C., Deckers J.W., van Duijn C.M., and Stricker B.H. Genetic polymorphisms and heart failure. Genet Med 6 6 (2004) 465-474 [Nov-Dec]
23. Hebert P.R., Foody J.M., and Hennekens C.H. The renin-angiotensin system: the role of inhibitors, blockers, and genetic polymorphisms in the treatment and prevention of heart failure. Curr Vasc Pharmacol 1 1 (2003) 33-39
24. Pasotti M., Repetto A., Tavazzi L., and Arbustini E. Genetic predisposition to heart failure. Med Clin North Am 88 5 (2004) 1173-1192
25. Crackower M.A., Sarao R., Oudit G.Y., et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 417 6891 (2002) 822-828
26. Danilczyk U., Eriksson U., Crackower M.A., and Penninger J.M. A story of two ACEs. J Mol Med 81 4 (2003) 227-234
27. Ishiyama Y., Gallagher P.E., Averill D.B., Tallant E.A., Brosnihan K.B., and Ferrario C.M. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension 43 5 (2004) 970-976
28. Yagil Y., and Yagil C. Hypothesis: ACE2 modulates blood pressure in the mammalian organism. Hypertension 41 4 (2003) 871-873
29. Burrell L.M., Johnston C.I., Tikellis C., and Cooper M.E. ACE2, a new regulator of the renin-angiotensin system. Trends Endocrinol Metab 15 4 (2004) 166-169
30. Byar D.P. Problems with using observational databases to compare treatments. Stat Med 10 (1991) 663-666
31. Tamblyn R., and Abrahamowicz M. Drug utilization patterns. In: Armitage P., and Colton T. (Eds). Encyclopedia of Biostatistics (1998), J Wiley, West Sussex, United Kingdom 1235-1247